High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

Blood

Volumn 106, Issue 12, 2005, Pages 3755-3759

  Bladé, Joan ^a   Rosiñol, Laura ^b   Sureda, Ana ^b   Ribera, Josep M ^b   Díaz Mediavilla, Joaquín ^b   García Laraña, José ^b   Mateos, M Victoria ^b   Palomera, Luis ^b   Fernández Calvo, Javier ^b   Martí, Josep M ^b   Giraldo, Pilar ^b   Carbonell, Félix ^b   Callís, Manel ^b   Trujillo, Jesús ^b   Gardella, Santiago ^b   Moro, M Jesús ^b   Barez, Abelardo ^b   Soler, Alfons ^b   Font, Llorenc ^b   Fontanillas, Montserrat ^b   San Miguel, Jesús ^b   more..

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; WHOLE BODY RADIATION;

EID: 28444494386     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-1301     Document Type: Article

References (28)

1. Crowley J, Jacobson JL, Alexanian R. Standarddose therapy for multiple myeloma: the Southwest Oncology Group experience. Semin Hematol. 2001;38:203-208.
2. Bladé J, San Miguel JF, Fontanillas M, et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA studies including 914 patients. Hematol J. 2001;2:272-278.
3. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan and prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
4. Hjorth M, Holmberg E, Rodjer S, et al. Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group. Eur J Haematol. 1999;62:271-277.
5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with haematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
7. Fermand JP, Ravaud P, Katsahian S, et al. Highdose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients aged 55 to 65 years of age [abstract]. Blood. 1999;94(suppl 1):396a.
8. Barlogie B, Kyle RA, Anderson KC, et al. Comparable survival in multiple myeloma (MM) with high-dose therapy (HDT) following MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup trial S9321 [abstract]. Blood. 2003;102:42a.
9. Bladé J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol. 2000;39:843-847.
10. Chronic Leukemia Myeloma Task Force. National Cancer Institute, II: plasma cell myeloma: proposed guidelines for protocol studies. Cancer Chemother Rep. 1973;4:145-158.
11. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958:53:457-481.
12. Peto R, Pike MC. Conservation of the approximation (O-E)/E in the log-rank test for survival data or tumor incidence data. Biometrics. 1973;29:579-584.
13. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
14. Kyle RA, Rajkumar SV. Treatment of multiple myeloma. N Engl J Med. 2004;351:1860-1873.
15. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med. 1983;308:314-316.
16. Alexanian R. Ten-year survival in multiple myeloma. Arch Intern Med. 1985;145:2073-2074.
17. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
18. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood. 2000;65:7-11.
19. Palumbo A, Triolo S, Argentino C, et al. Doseintensive melphalan with stem cell support (MEL-100) is superior to standard treatment in elderly myeloma patients. Blood. 1999;94:1248-1253.
20. Bladé J, Vesole DH, Gertz MA. Transplantation for multiple myeloma: who, when, how often? Blood. 2003;102:3469-3477.
21. Bladé J, Esteve J, Rives S, et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission: fesults from a nonrandomized study from a single institution. Bone Marrow Transplant. 2000;26:845-849.
22. Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27:1037-1043.
23. Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112:814-819.
24. Bladé J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol. 1996;14:2167-2173.
25. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood. 1994;84:4278-4282.
26. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivates. J Clin Oncol. 2003;21:4444-4454.
27. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
28. Alexanian R, Wang L, Weber D, et al. VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma [abstract]. Blood. 2004;204:64a.